Canadian researchers discover Parkinson's clue

Afp
Friday 08 April 2011 00:00 BST
Comments

Your support helps us to tell the story

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.

At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.

The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.

Your support makes all the difference.

A Canadian-led study has discovered that a gene mutation in Parkinson's patients prevents brain cells from purging a key protein linked to the degenerative disease, researchers said Wednesday.

"This study addresses a major riddle in Parkinson's disease," said lead study author Michael Schlossmacher, who holds the Canada Research Chair in Parkinson's disease at the Ottawa Hospital Research Institute and the University of Ottawa.

It was known that 10-12 percent of people with Parkinson's have a mutation in one copy of a gene called glucocerebrosidase, or GBA.

But how these mutations contributed to the disease or how they fit with other pieces of the puzzle, such as the gradual accumulation of the protein alpha-synuclein in the brain as Parkinson's progresses, was not previously understood.

Affected brain cells show signs of injury, and when they die, this leads to the tremors, stiffness and slowness that are typically associated with Parkinson's disease.

Schlossmacher and his colleagues showed in a series of experimental laboratory models that the mutations prevent brain cells from efficiently breaking down and removing alpha-synuclein.

"While the GBA mutations don't cause Parkinson's disease on their own, they do significantly increase the risk of developing the disease, probably by making people susceptible to the accumulation of alpha-synuclein," he said.

"This could explain why people with GBA mutations frequently develop Parkinson's symptoms four to five years earlier than those without them."

The study provides the first link between the most common genetic risk factor for Parkinson's and the hallmark accumulation of the protein alpha-synuclein within the brains of people with Parkinson's.

Schlossmacher said the discovery, chronicled in the latest issue of the journal Annals of Neurology, could lead to new treatments.

str/amc/ao

Join our commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in